Skip to main content
    I

    Immunitybio Inc (IBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.26
    +0.28 (+4.68%)

    Market Cap: $6.40B

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Immunitybio Inc (IBRX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Immunitybio (IBRX) has a market cap of $6.40B and an enterprise value of $7.62B. It kept -454.49% of revenue as net income over the last 12 months. Revenue grew 149.99% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 18.99% above the market cap, as debt exceeds cash.

    Market Cap$6.40B
    Enterprise Value$7.62B
    Latest price (Nov 17, 2026)$6.26

    Key Dates

    The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 22, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.97% in the quarter ended Sep 30, 2026 and grew 23.43% a year over 2 years.

    Shares Outstanding1.06B
    Shares Change (YoY)+12.00%
    Shares Change (QoQ)+0.97%
    Share Count Growth (2Y CAGR)+23.43%

    Valuation Ratios

    The price to sales ratio is 31.8x. Its year-end P/S ranged from 13.3x to 550.1x from 2019 to 2025.

    P/S Ratio31.8x
    Forward P/S32.0x

    Price Statistics

    The stock is up 200.96% over 52 weeks and trades 26.44% below its 50-day average.

    Beta (1Y)1.40
    52-Week Change+200.96%
    1-Month Change-25.65%
    3-Month Change-23.00%
    6-Month Change-19.33%
    5-Year Change+5.87%
    10-Year Change+38.40%
    Total Return (1Y)+200.96%
    Total Return (3Y CAGR)+14.77%
    Total Return (5Y CAGR)-0.84%
    Return vs SPY (1Y)+186.54%
    Max Drawdown (1Y)-48.23%
    Max Drawdown (3Y)-79.34%
    Sharpe Ratio (1Y)1.05
    Correlation with SPY (1Y)0.19
    50-Day Average$8.51
    200-Day Average$7.97
    52-Week Range$1.95 to $12.43
    RSI (14 Days)35.7
    Average Volume (20 Days)12.87M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.27x current liabilities.

    Current Ratio4.27x
    Quick Ratio4.27x
    Interest Coverage-10.06x

    Returns and Efficiency

    Return on invested capital is -780.52% over the last 12 months.

    Return on Assets (ROA)-155.87%
    Return on Invested Capital (ROIC)-780.52%
    Return on Capital Employed (ROCE)-175.60%
    ROA (5Y Average)-96.71%
    Asset Turnover0.37x
    Inventory Turnover1.95x
    Receivables Turnover3.90x
    Cash Conversion Cycle-7813 days

    Scores

    IBRX has an Altman Z-Score of -12.59, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score-12.59
    Altman Z ZoneDistress
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $209.00M over the last 12 months.

    Revenue$209.00M
    Revenue Growth (YoY)+149.99%
    Gross Profit$207.10M
    Operating Income-$147.24M
    Pretax Income-$950.22M
    Net Income-$949.86M
    EBIT-$897.83M
    Reported EPS (TTM)-$0.32

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$45.08M
    Total Debt$1.26B
    Net Debt$1.22B
    Net Debt Per Share$1.15
    Working Capital$320.70M
    Shareholder Equity-$1.15B
    Tangible Book Value-$1.16B
    Total Assets$609.39M
    Total Liabilities$1.75B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $9.56M of capital spending, operating cash flow left -$297.13M of free cash flow.

    Operating Cash Flow-$287.56M
    Capital Expenditures$9.56M
    Free Cash Flow-$297.13M
    FCF Per Share-$0.28
    Depreciation and Amortization$24.69M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -70.45%.

    Gross Margin99.09%
    Operating Margin-70.45%
    Pretax Margin-454.66%
    Net Margin-454.49%
    EBIT Margin-429.59%
    FCF Margin-142.17%
    Gross Margin (5Y Average)99.87%

    Growth

    Revenue grew 678.62% a year over 3 years.

    Revenue Growth (3Y CAGR)+678.62%
    Revenue Growth (5Y CAGR)+184.76%

    Revenue and profit by year

    Dividends and Yields

    IBRX does not pay a dividend. Its free cash flow yield is -4.48%.

    FCF Yield-4.48%
    Buyback Yield-1.24%
    Shareholder Yield-1.24%

    Peer Position

    Against 4 similar companies, IBRX has the 2nd highest P/S.

    P/S Ratio31.8x vs 10.1x median
    ROIC-780.52% vs -43.38% median
    Revenue Growth (Trailing 4 Quarters, YoY)+149.99% vs +39.49% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 100.41% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+100.41%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IBRX

    What is IBRX's market cap?

    Immunitybio has a market cap of $6.40B. Its enterprise value, which adds debt and subtracts cash, is $7.62B.

    How many shares of IBRX are outstanding?

    Immunitybio has 1.06B shares outstanding. The count is up 12.00% from a year earlier.

    Does IBRX pay a dividend?

    No. Immunitybio does not pay a dividend.

    How much debt does IBRX have?

    Immunitybio has $1.26B of total debt and $45.08M of cash and equivalents, a net debt position of $1.22B.